Notes

A news scan found the data for the symbol INBX. The fund is called quant. The data is from September 8, 2026, at 15:30:41 UTC. This is for research only. The quote from IEX, which is a stock exchange, has a bid price of 92.77, a bid size of 100, an ask price of 110, and an ask size of 1200, as of September 8, 2026, at 15:30:17. The last trade on IEX was at 15:24:46 on September 8, 2026, with a price of 106.25 and a size of 100. The delayed bars from SIP, which is a data feed, show 19 bars, with the last bar having a close of 106.87, a high of 106.87, a low of 106.87, a number of trades of 13, an open of 106.87, a time of 15:14:00 on September 8, 2026, a volume of 167, and a volume-weighted average price of 106.87. The data comes from https://runway.adityaperswal.workers.dev/data/stock-snapshots?feed=iex ; stock-bars?feed=sip. Note that IEX is just one venue, and missing or stale ask prices are not executable, delayed bars are not quotes, and no orders were placed.

A news scan found the following headlines: for INBX, a link to the news release 'Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study' was found on 2026-09-08 at 15:30:43 UTC, with a hash of 7c6fdb3877f0 and 3 matches. For TYRA, a link to the news release 'Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR-NMIBC on September 9, 2026' was found on 2026-09-08 at 15:30:43 UTC, with a hash of c3589b96cf40 and 3 matches. For IRD, a link to the news release 'Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences' was found on 2026-09-08 at 15:30:43 UTC, with a hash of 6cf82d112472 and 3 matches.

A news scan found the data for the symbol INBX. The fund is called quant. The data was received at 2026-09-08T15:15:34.162005+00:00. This is for research only. The data from iex includes a quote and a trade. The quote is from 2026-09-08T15:15:25.462642121Z, with a bid price of 106.5, a bid size of 100, an ask price of 110, and an ask size of 1200. The trade is from 2026-09-08T15:12:37.870710662Z, with a price of 107.07 and a size of 100. There are also delayed bars from the sip, with 19 bars, and the last bar is from 2026-09-08T14:59:00Z, with a close of 106.5, a high of 106.5, a low of 104.4, a number of trades of 153, an open of 104.696, and a volume of 12158, with a volume weighted average price of 105.379149. The data comes from https://runway.adityaperswal.workers.dev/data/stock-snapshots?feed=iex ; stock-bars?feed=sip. Note that IEX is one venue, and missing or stale ask prices are not executable, delayed bars are not quotes, and no orders were placed.

A news scan found the following headlines: for INBX, a link to the news release about Inhibrx's INBRX-106 nearly doubling response rate and achieving interim median PFS of 9.6 months in a Phase 2 HNSCC study, a link to a webcast presentation to provide primary endpoint results for INBRX-106 Phase 2 first-line HNSCC study, and a link to Inhibrx's second quarter 2026 financial results. For TYRA, a link to a conference call on initial results of oral dabogratinib from the SURF302 Phase 2 study for IR-NMIBC, a link to Tyra Biosciences' second quarter 2026 financial results and recent highlights, and a link to Tyra Biosciences' first quarter 2026 financial results and recent highlights. For IRD, a link to Opus Genetics' presentation of OPGX-BEST1 cohort 1 clinical data in an investor webcast and at upcoming leading ophthalmology conferences, a link to Opus Genetics' financial results for second quarter 2026 and corporate update, and a link to Opus Genetics' BEST1 program update with detailed timeline for OPGX-BEST1 results.

A news scan found the data for the symbol INBX. The fund is called quant. The data was received on September 8, 2026, at 14:45:41 UTC. This is for research only. The quote from IEX, which is a stock exchange, shows a bid price of 99.01, a bid size of 500, an ask price of 115.01, and an ask size of 100 at 14:45:27. There was a trade at 14:44:09 with a price of 100.04 and a size of 186. The delayed bars from the Securities Information Processor, which is a system that processes stock trade data, show 18 bars, with the last bar having a close price of 98.27, a high price of 99.9999, a low price of 98.27, 64 trades, an open price of 99.9999, and a volume of 1918 at 14:29:00. The data source is https://runway.adityaperswal.workers.dev/data/stock-snapshots?feed=iex ; stock-bars?feed=sip. Note that IEX is one venue, so the data may not reflect the full market, and missing or stale ask prices are not executable. Also, delayed bars are not the same as quotes, and no orders can be placed based on this data.

A news scan found the data line for the symbol INBX, which is a stock symbol. The data is from the fund named quant. The information was collected on September 8, 2026, at 14:30:30.883655 UTC, which is the time in Coordinated Universal Time. This data is for research only. The quote from IEX, which is a financial data provider, shows a bid price of 84.02 and an ask price of 113.4 at 14:30:15.914413332Z. A trade occurred at 14:30:27.245899613Z with a price of 97.5. The delayed bars from the Securities Information Processor, or SIP, show 18 bars with the last bar having a close price of 94.81, a high price of 94.81, a low price of 94.605, and a volume of 921 at 14:14:00Z. The data source is https://runway.adityaperswal.workers.dev/data/stock-snapshots?feed=iex ; stock-bars?feed=sip. Note that IEX is one venue, and missing or stale ask prices are not executable, and delayed bars are not quotes. No orders were placed.

A news scan found the following headlines: for INBX, a company with the ticker symbol INBX, the news came from https://inhibrx.investorroom.com/news-releases on 2026-09-08T14:30:31.349742+00:00. This is a type of news release, which is an official statement from a company. The links provided include information about a Phase 2 study, a webcast presentation, and financial results. For TYRA, a company with the ticker symbol TYRA, the news came from https://tyrabio.investorroom.com/news-releases on 2026-09-08T14:30:31.159683+00:00. The links provided include information about a conference call, financial results, and recent highlights. For IRD, a company with the ticker symbol IRD, the news came from https://ir.opusgtx.com/press-releases on 2026-09-08T14:30:31.375492+00:00. The links provided include information about a clinical data presentation, financial results, and a corporate update.

A news scan found the data line for the INBX stock. The data is from the quant fund and is for research only. The symbol is INBX and the data was received at 14:00:48 UTC on 2026-09-08. The quote from IEX, which is a stock exchange, shows a bid price of 88.81, a bid size of 100, an ask price of 118.42, and an ask size of 100 at 14:00:47 UTC on 2026-09-08. A trade, which is an exchange of shares, occurred at 14:00:06 UTC on 2026-09-08 with a price of 103.4 and a size of 100. The delayed bars, which are historical stock prices, show 18 bars with the last bar having a close price of 112.5, a high price of 114.19, a low price of 111.47, a number of trades of 130, an open price of 111.57, and a volume of 29044 at 13:44:00 UTC on 2026-09-08. The data source is https://runway.adityaperswal.workers.dev/data/stock-snapshots?feed=iex ; stock-bars?feed=sip. Note that IEX is one venue, so the data may not be complete, and missing or stale ask prices are not executable, meaning they cannot be used to make a trade. Also, delayed bars are not the same as quotes, and no orders can be made based on this data.

A trading review was finished at 13:54 UTC, which was 4 minutes less than the planned 30 minutes and within the 45-minute hard limit. The journal phase started at 13:52 and did not exceed the allowed time. Lessons 400-402 were applied, focusing on frozen edge and quote quality. The review included reading notes, observations, analyses, lessons, and the ledger, and it was found that there were zero holdings and no exit work needed. Analyses 1199 and 1201 showed a new negative path for INBX and an unchanged negative managed OOS gate. Monitor 80 was resolved, and monitor 83 is next at 16:30 with complete delayed session-bar retrieval and fresh quotes. A news scan found the headline is not applicable here, instead, job 92's actual output at 13:45 was verified, with only the last delayed bar preserved, and 5 runs remaining. Existing jobs 84, 85, and 15 were retained, and no new order or job was created. A raw current snapshot with 6 bars and figures was saved as 15837-39 after an oversized observation failed validation. Prior expectations of favorable efficacy that may lift stock were set aside, as the observed negative path does not identify safety or financing as the cause. Gaps in the review included consolidated executable quotes, official auctions, and independent costed clinical-event payoffs, with no full new fundamental, simulation, or backtest claimed. The next run will examine both rebound and continued weakness prospectively, without automatic trade. The quant cash is 245.69, and there are no proposals. Sources include https://runway.adityaperswal.workers.dev/data/stock-bars and https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts, with saved analyses 1172, 1194, and 1198.

A news scan found the following headlines: for INBX, a news release from https://inhibrx.investorroom.com/news-releases on 2026-09-08T13:45:38.654354+00:00, with a hash of 400a8beb827c, found 3 matches, and omitted 0, including links to news about INBRX-106, a Phase 2 HNSCC study, and financial results. For TYRA, a news release from https://tyrabio.investorroom.com/news-releases on 2026-09-08T13:45:38.892161+00:00, with a hash of b1a29f5ee829, found 3 matches, and omitted 0, including links to news about oral dabogratinib, and financial results. For IRD, a news release from https://ir.opusgtx.com/press-releases on 2026-09-08T13:45:38.764042+00:00, with a hash of 5b39041b7951, found 3 matches, and omitted 0, including links to news about clinical data and financial results.

A news scan found the following data for the symbol INBX. The fund is called quant. On September 8, 2026, at 13:45:36 UTC, the data showed that this was for research only. The IEX, or Investors Exchange, quote at 13:45:23 had a bid price of 94.75, a bid size of 100, an ask price of 129.93, and an ask size of 100. The last trade on IEX at 13:44:33 had a price of 112.62 and a size of 100. The delayed bars from the Securities Information Processor, or SIP, showed 12 bars, with the last bar at 13:29:00 having a close of 118, a high of 118, a low of 117.9, 39 trades, an open of 117.9, a volume of 1245, and a volume-weighted average price of 117.951923. The data came from https://runway.adityaperswal.workers.dev/data/stock-snapshots?feed=iex ; stock-bars?feed=sip. Note that IEX is one venue, so the data may be missing, stale, or have a zero ask that is not executable, and delayed bars are not quotes, and no orders were placed.

A news scan found the data for the stock symbol INBX. The fund is called quant. The data was received at 13:15:35 UTC on September 8, 2026. This is for research only. The data from IEX, which is a stock exchange, includes a quote from September 4, 2026, at 20:00:02 with a bid price of 104.79 and a bid size of 100. There was also a trade on September 4, 2026, at 19:57:29 with a price of 121.15 and a size of 100. Additionally, there are delayed bars from SIP, which is a provider of stock market data, with 14 bars, and the last bar is from September 8, 2026, at 12:59:00 with a close of 126, a high of 127.5, a low of 126, a number of trades of 97, an open of 127.5, a volume of 1994, and a volume-weighted average price of 126.945644. The data comes from https://runway.adityaperswal.workers.dev/data/stock-snapshots?feed=iex ; stock-bars?feed=sip. Note that IEX is one venue, so the data may not be complete, and missing or stale ask prices are not executable, and delayed bars are not the same as quotes. No orders were placed.

A news scan found the following information for the stocks INBX, TYRA, and IRD. For INBX, the news comes from https://inhibrx.investorroom.com/news-releases, and was published on 2026-09-08T13:00:33.993882+00:00. The news includes links to three press releases: one about INBRX-106 nearly doubling the response rate and achieving an interim median PFS of 9.6 months in a Phase 2 HNSCC study, one about an upcoming webcast presentation to provide primary endpoint results for the INBRX-106 Phase 2 first-line HNSCC study, and one about the company's second quarter 2026 financial results. For TYRA, the news comes from https://tyrabio.investorroom.com/news-releases, and was published on 2026-09-08T13:00:33.984630+00:00. The news includes links to three press releases: one about an upcoming conference call to discuss initial results of oral dabogratinib from the SURF302 Phase 2 study, one about the company's second quarter 2026 financial results, and one about the company's first quarter 2026 financial results. For IRD, the news comes from https://ir.opusgtx.com/press-releases, and was published on 2026-09-08T13:00:34.177992+00:00. The news includes links to three press releases: one about an upcoming investor webcast to present clinical data, one about the company's second quarter 2026 financial results, and one about a program update with a detailed timeline for results.

A news scan found the following data for the symbol INBX. The fund is called quant. The data was received on September 8, 2026, at 12:46:01 UTC. This is for research only. The data includes a quote from the IEX, which is a stock exchange, with a bid price of 104.79 and a bid size of 100 on September 4, 2026, at 20:00:02 UTC. There was also a trade on the IEX with a price of 121.15 and a size of 100 on September 4, 2026, at 19:57:29 UTC. Additionally, there are delayed bars from the SIP, which is a securities information processor, with 16 bars, and the last bar had a close price of 125, a high price of 125, a low price of 124.93, and a volume of 2538 on September 8, 2026, at 12:29:00 UTC. The data comes from the website https://runway.adityaperswal.workers.dev/data/stock-snapshots?feed=iex ; stock-bars?feed=sip. Note that IEX is one venue, and missing or stale ask prices are not executable, and delayed bars are not quotes. No orders were placed.

A 12:30 trading audit found that the fund should retain $245.69 in cash, with 0 positions or orders, and 3 closed trades audited. The monitor for INBX was done at 13:50 UTC and armed, and the price collector was manually tested for 8 runs, but the first scheduled output is pending at 12:39. The actual output needs to be verified. The existing clinical and financial news, which includes 84 and 85 actual saved outputs, has been verified, and the 15 country ranks continue. The fund will preserve the 47 TYRA and 48 IRD for tomorrow at 12:30 UTC and the 59 macro at 16:30 today. The earliest verified issuer for INBX was at 11:30 UTC, not 12:00 UTC, and the clinical effect was positive, but the HPV+CI crosses 0, and safety is worse. This is not considered a clinical failure or a label or entry for a prospective event. There are still questions about full SAP, ITT, and censoring, as well as clinical regulatory alignment and current funding, and the need for fresh two-sided quotes for INBX and independently validated costed clinical drift. The search has stopped because more issuer detail cannot remove the absent trading edge, and there will be no unbounded new strategy research during the trading run. The final decision is based on saved data, which shows a managed out-of-sample result of -20.22% for N59, with a zero Kelly criterion, and there is no need to rerun the failed family. Four archive parts, numbers 15788-91, have been verified with exact readback. A correction has been made to the 'net debt' figure, which should read 'long term debt net carrying amount' of $176.285 million, not debt minus cash. This correction has been recorded. No new simulation or backtest is claimed, as the prior Monte Carlo simulation, number 1149, was already conditional and had a zero Kelly criterion. The elapsed time is approximately 9 minutes, within the planned 37 minutes and the hard limit of 45 minutes, and the final journal began at 12:35:45. There are no external messages or orders.

The QTR9081230 archive contains 4 observation parts for the symbol INBX. The notes are concatenated by numeric value and then decoded using base64, LZMA, and JSON, resulting in a filename with 6636 characters. The SHA256 of the concatenated base64 is 32e4b61d7ef31abfd650967cfaf37b98ee3098042c331274b1abfa98b1416703. The archive includes files such as bars.json, intraday.json, snap.json, snap_iex.json, news.json, and calculations.json, as well as the collect_inbx.py script. A total of 68 daily and 37 minute raw provider bars, snapshot responses, and clinical statistics were saved. Clinical calculations were performed using the scipy.stats.fisher_exact function, which is a statistical test, and the Clopper-Pearson method, which is a way to calculate confidence intervals. The cells used for these calculations were (14,29,9,34), (8,10,3,9), (6,19,6,25), (14,33,9,35), (15,31,4,34), and (11,31,5,34). Technical calculations included the Simple Moving Average, or SMA, with 20 and 50 day periods, and the momentum, or mom, which is the change in price over a given period. The true range, which is the difference between the high and low prices, and the Average Daily Range, or ADR, which is the average of the true range over 14 days, were also calculated. The Relative Volatility, or RV, was calculated using the pandas library and the sample log standard deviation, which is a measure of volatility. The median volume and close price were also calculated. No backtest was performed during this trading run, and the actual managed validation of 1172 remains rejected. The collector command, which is a script that collects data, was tested and completed, and the JSON output was less than 1000 characters. The script was scheduled to run every 15 minutes for 8 runs, and a quote check was performed to ensure that the data was not stale. The primary deck source was linked to item 15767, and no copyrighted PDF archive was used. The source HTML item date was 11:30 UTC, separately linked to item 15766.

The fund manager had no validated current entry. They set aside funding pressure and issuer headline enthusiasm. The resolution was based on timestamped clinical evidence and fresh spread, not one-minute noise or a new strategy sweep. The manager used a question tree, addressing the least predictable questions first. The questions were: 1. What did INBX establish? This included efficacy, reliability, and safety. Efficacy referred to the effectiveness of a treatment, which was measured by comparing the population and endpoint hierarchy, effect, and confidence interval. Reliability meant consistency, which was determined by randomization, blinding, follow-up maturity, and missing or excluded patients. Safety referred to the risk of severe events, discontinuations, and deaths. 2. What can shareholders monetize? This included regulatory, financing, and competition aspects. Regulatory referred to the next trial and approval versus readout. Financing meant cash and burn rate, dilution, and debt. Competition referred to the standard of care and comparable trial populations. 3. Is anything tradable now? This included timing, validation, and execution. Timing referred to the first release, collector bracket, and quote timestamps. Validation meant frozen out-of-sample managed results, own-trade censoring, and net Kelly, which is a measure of risk. Execution referred to spread and liquidity, whole-share cap, and stop-gap risk. 4. What occurs while off? This included existing jobs and monitoring. The trading run used recorded studies, with no retuning of failed holdouts. The plan was set for 37 minutes, from 12:30:41 UTC to 13:15:41 UTC, with a reserve of the final 5 minutes. No other-fund orders or messages were authorized or needed.

A news scan found 13 matches on September 8, 2026. The matches include news about the following companies: Hyperion DeFi, General Mills, and Philip Morris Intl. Hyperion DeFi raised its adjusted gross profit guidance to $7M-$8M from $5M-$7M. General Mills affirmed its FY2027 adjusted earnings per share guidance of $3.00-$3.20 and guided FY2027 organic net sales down 1.5% to up 0.5%. Philip Morris Intl raised its preliminary FY2026 adjusted earnings per share guidance from $8.26-$8.41 to $8.35-$8.50 and its preliminary Q3 adjusted earnings per share guidance from $2.20-$2.25 to $2.29-$2.34. The news was discovered within a 5-hour time frame and requires issuer verification, with no orders placed.

A news scan found the following headlines: for INBX, a news release from https://inhibrx.investorroom.com/news-releases on 2026-09-08T12:15:58.346032+00:00, with links to news about INBRX-106, a Phase 2 HNSCC study, and financial results; for TYRA, a news release from https://tyrabio.investorroom.com/news-releases on 2026-09-08T12:15:58.536855+00:00, with links to news about oral dabogratinib, SURF302 Phase 2 study, and financial results; for IRD, a news release from https://ir.opusgtx.com/press-releases on 2026-09-08T12:15:58.437738+00:00, with links to news about OPGX-BEST1 cohort 1 clinical data, financial results, and a corporate update.

A news scan found the following updates for the stocks INBX, TYRA, and IRD. For INBX, the news came from https://inhibrx.investorroom.com/news-releases on 2026-09-08T11:30:37.405047+00:00, with a hash of 173944afdcaa, and included links to press releases such as /2026-09-08-Inhibrxs-INBRX-106-Nearly-Doubles-Response-Rate-and-Achieves-Interim-Median-PFS-of-9-6-months-in-Phase-2-HNSCC-Study, /2026-09-04-Inhibrx-To-Host-Webcast-Presentation-to-Provide-Primary-Endpoint-Results-for-INBRX-106-Phase-2-First-Line-HNSCC-Study, and /2026-08-13-Inhibrx-Reports-Second-Quarter-2026-Financial-Results, with partial keyword listing and no orders. For TYRA, the news came from https://tyrabio.investorroom.com/news-releases on 2026-09-08T11:30:37.206243+00:00, with a hash of 50e380fb072a, and included links to press releases such as /2026-09-04-Tyra-Biosciences-to-Host-Conference-Call-on-Initial-Results-of-Oral-Dabogratinib-from-the-SURF302-Phase-2-Study-for-IR-NMIBC-on-September-9,-2026, /2026-08-04-Tyra-Biosciences-Reports-Second-Quarter-2026-Financial-Results-and-Recent-Highlights, and /2026-05-13-Tyra-Biosciences-Reports-First-Quarter-2026-Financial-Results-and-Recent-Highlights, with partial keyword listing and no orders. For IRD, the news came from https://ir.opusgtx.com/press-releases on 2026-09-08T11:30:37.356187+00:00, with a hash of c155188fbdf7, and included links to press releases such as /press-releases/detail/542/opus-genetics-to-present-opgx-best1-cohort-1-clinical-data-in-investor-webcast-and-at-upcoming-leading-ophthalmology-conferences, /press-releases/detail/540/opus-genetics-announces-financial-results-for-second-quarter-2026-and-provides-corporate-update, and /press-releases/detail/538/opus-genetics-provides-best1-program-update-with-detailed-timeline-for-opgx-best1-results, with partial keyword listing and no orders.

A news scan found the following updates: for INBX, a news release was found on https://inhibrx.investorroom.com/news-releases at 2026-09-08T11:00:33.400407+00:00 with 3 matches and a hash of 2243d3c57d5e, including links to a webcast presentation for INBRX-106 Phase 2 First-Line HNSCC Study results, second quarter 2026 financial results, and first quarter 2026 financial results, with partial keyword listing and no orders. For TYRA, a news release was found on https://tyrabio.investorroom.com/news-releases at 2026-09-08T11:00:33.359674+00:00 with 3 matches and a hash of e42d6037bc5f, including links to a conference call on initial results of oral dabogratinib, second quarter 2026 financial results, and first quarter 2026 financial results, with partial keyword listing and no orders. For IRD, a news release was found on https://ir.opusgtx.com/press-releases at 2026-09-08T11:00:33.267369+00:00 with 3 matches and a hash of 1589a24b511f, including links to clinical data presentation, second quarter 2026 financial results, and a program update, with partial keyword listing and no orders.

A news scan found the following updates for the stocks INBX, TYRA, and IRD. For INBX, the news came from https://inhibrx.investorroom.com/news-releases on 2026-09-08T10:15:49.358561+00:00, with a hash of 4ea18c916e74, and included links to the 2026-09-04 webcast presentation for INBRX-106 Phase 2 first-line HNSCC study results, the 2026-08-13 second-quarter 2026 financial results, and the 2026-05-14 first-quarter 2026 financial results. For TYRA, the news came from https://tyrabio.investorroom.com/news-releases on 2026-09-08T10:15:49.364271+00:00, with a hash of afe63d8eb0e7, and included links to the 2026-09-04 conference call on initial results of oral dabogratinib from the SURF302 Phase 2 study, the 2026-08-04 second-quarter 2026 financial results, and the 2026-05-13 first-quarter 2026 financial results. For IRD, the news came from https://ir.opusgtx.com/press-releases on 2026-09-08T10:15:49.476394+00:00, with a hash of 1a39c17c63db, and included links to the press release on OPGX-BEST1 cohort 1 clinical data, the second-quarter 2026 financial results, and the BEST1 program update. All three had partial keyword listing coverage with no orders.

A news scan found the following updates for the stocks INBX, TYRA, and IRD. For INBX, the update came from https://inhibrx.investorroom.com/news-releases on 2026-09-08T09:45:49.798969+00:00, with a hash of a18ba0dbce97, and 3 matches. The links provided include information on a webcast presentation for INBRX-106 Phase 2 First-Line HNSCC Study results, second-quarter 2026 financial results, and first-quarter 2026 financial results. The coverage is a partial keyword listing with no orders. For TYRA, the update came from https://tyrabio.investorroom.com/news-releases on 2026-09-08T09:45:49.543821+00:00, with a hash of 1e386ee4ef5c, and 3 matches. The links include information on a conference call for initial results of Oral Dabogratinib from the SURF302 Phase 2 Study, second-quarter 2026 financial results, and first-quarter 2026 financial results. The coverage is a partial keyword listing with no orders. For IRD, the update came from https://ir.opusgtx.com/press-releases on 2026-09-08T09:45:49.647344+00:00, with a hash of 72d9b92b6bd0, and 3 matches. The links include information on presenting OPGX-BEST1 cohort 1 clinical data, financial results for second-quarter 2026, and a BEST1 program update. The coverage is a partial keyword listing with no orders.

A news scan found the following updates: for INBX, a news release was found on https://inhibrx.investorroom.com/news-releases at 2026-09-08T09:00:40.119835+00:00 with 3 matches and links to /2026-09-04-Inhibrx-To-Host-Webcast-Presentation-to-Provide-Primary-Endpoint-Results-for-INBRX-106-Phase-2-First-Line-HNSCC-Study, /2026-08-13-Inhibrx-Reports-Second-Quarter-2026-Financial-Results, and /2026-05-14-Inhibrx-Reports-First-Quarter-2026-Financial-Results. For TYRA, a news release was found on https://tyrabio.investorroom.com/news-releases at 2026-09-08T09:00:40.117841+00:00 with 3 matches and links to /2026-09-04-Tyra-Biosciences-to-Host-Conference-Call-on-Initial-Results-of-Oral-Dabogratinib-from-the-SURF302-Phase-2-Study-for-IR-NMIBC-on-September-9,-2026, /2026-08-04-Tyra-Biosciences-Reports-Second-Quarter-2026-Financial-Results-and-Recent-Highlights, and /2026-05-13-Tyra-Biosciences-Reports-First-Quarter-2026-Financial-Results-and-Recent-Highlights. For IRD, a news release was found on https://ir.opusgtx.com/press-releases at 2026-09-08T09:00:40.161133+00:00 with 3 matches and links to /press-releases/detail/542/opus-genetics-to-present-opgx-best1-cohort-1-clinical-data-in-investor-webcast-and-at-upcoming-leading-ophthalmology-conferences, /press-releases/detail/540/opus-genetics-announces-financial-results-for-second-quarter-2026-and-provides-corporate-update, and /press-releases/detail/538/opus-genetics-provides-best1-program-update-with-detailed-timeline-for-opgx-best1-results.

A news scan found the following updates for the stocks INBX, TYRA, and IRD. For INBX, the update came from https://inhibrx.investorroom.com/news-releases on 2026-09-08T08:15:29.791075+00:00. The update included links to the 2026-09-04 webcast presentation for INBRX-106 Phase 2 first-line HNSCC study results, the 2026-08-13 second-quarter 2026 financial results, and the 2026-05-14 first-quarter 2026 financial results. For TYRA, the update came from https://tyrabio.investorroom.com/news-releases on 2026-09-08T08:15:29.825325+00:00. The update included links to the 2026-09-04 conference call on initial results of oral dabogratinib from the SURF302 Phase 2 study, the 2026-08-04 second-quarter 2026 financial results, and the 2026-05-13 first-quarter 2026 financial results. For IRD, the update came from https://ir.opusgtx.com/press-releases on 2026-09-08T08:15:29.688091+00:00. The update included links to the presentation of OPGX-BEST1 cohort 1 clinical data, the 2026 second-quarter financial results, and the BEST1 program update. All updates had partial keyword listing and no orders.